BETA BLOCKADE IN MITRAL REGURGITATION

β 阻断治疗二尖瓣反流

基本信息

  • 批准号:
    2028292
  • 负责人:
  • 金额:
    $ 17.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1988
  • 资助国家:
    美国
  • 起止时间:
    1988-03-01 至 1997-11-30
  • 项目状态:
    已结题

项目摘要

Mitral regurgitation (MR) imposes a volume overload on the left ventricle which eventually leads to left ventricular dysfunction. Such dysfunction is associated with subsequent morbidity and increased operative mortality. In the initial funding period, we developed a closed-chest chordal rupture model of severe MR, the consequence of which was inevitable left ventricular dysfunction. Thus, we have developed a tool to examine the causes of left ventricular dysfunction in MR. Using this tool: 1) We found that in vivo left ventricular dysfunction correlated closely with the dysfunction of myocytes isolated from the affected ventricle which in turn correlated with the loss of myocyte myofibrils. 2) Excitingly, we found that both the myocyte and ventricular dysfunction were reversible if the regurgitation was corrected by mitral valve replacement. Having defined that left ventricular dysfunction in MR was a reversible property of the myocyte due to myofibrillar loss, we then sought specific mechanisms by which the cell dysfunction occurred. Pilot studies which form the basis of this proposal demonstrated that beta-blockade in MR resulted in striking improvement of both the left ventricular dysfunction and myocyte dysfunction with a return of myofibrillar density toward normal levels. These data suggest that beta-adrenergic overstimulation is one cause of the ventricular dysfunction in experimental MR. In the current proposal, we will complete these pilot studies and cement this premise. Once this is established, we will then address three specific mechanisms by which beta-adrenergic overstimulation could be causing the dysfunction: 1) That tachycardia which occurs with dysfunction and is reduced with beta-blockade is or is not the cause of the negative effects of beta overstimulation and the positive effects of beta-blockade. 2) That although beta-receptor up-regulation occurs with beta-blockade and may be important in the left ventricular response to stress, the primary mechanism by which contractile function is improved by beta-blockade is enhanced innate contractile function. We will test this hypothesis by examining changes in isolated myocyte contractile function in a preparation devoid of adrenergic stimulation. 3) We will determine whether the increased myofibrillar density which must be in part responsible for the improvement seen following a beta- adrenergic blockade is due to a beta-blocker-induced increase in protein synthesis or a decrease in protein degradation.
Mitral regurgitation (MR) imposes a volume overload on the left ventricle which eventually leads to left ventricular dysfunction. Such dysfunction is associated with subsequent morbidity and increased operative mortality. In the initial funding period, we developed a closed-chest chordal rupture model of severe MR, the consequence of which was inevitable left ventricular dysfunction. Thus, we have developed a tool to examine the causes of left ventricular dysfunction in MR. Using this tool: 1) We found that in vivo left ventricular dysfunction correlated closely with the dysfunction of myocytes isolated from the affected ventricle which in turn correlated with the loss of myocyte myofibrils. 2) Excitingly, we found that both the myocyte and ventricular dysfunction were reversible if the regurgitation was corrected by mitral valve replacement. Having defined that left ventricular dysfunction in MR was a reversible property of the myocyte due to myofibrillar loss, we then sought specific mechanisms by which the cell dysfunction occurred. Pilot studies which form the basis of this proposal demonstrated that beta-blockade in MR resulted in striking improvement of both the left ventricular dysfunction and myocyte dysfunction with a return of myofibrillar density toward normal levels. These data suggest that beta-adrenergic overstimulation is one cause of the ventricular dysfunction in experimental MR. In the current proposal, we will complete these pilot studies and cement this premise. Once this is established, we will then address three specific mechanisms by which beta-adrenergic overstimulation could be causing the dysfunction: 1) That tachycardia which occurs with dysfunction and is reduced with beta-blockade is or is not the cause of the negative effects of beta overstimulation and the positive effects of beta-blockade. 2) That although beta-receptor up-regulation occurs with beta-blockade and may be important in the left ventricular response to stress, the primary mechanism by which contractile function is improved by beta-blockade is enhanced innate contractile function. We will test this hypothesis by examining changes in isolated myocyte contractile function in a preparation devoid of adrenergic stimulation. 3) We will determine whether the increased myofibrillar density which must be in part responsible for the improvement seen following a beta- adrenergic blockade is due to a beta-blocker-induced increase in protein synthesis or a decrease in protein degradation.

项目成果

期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
THE EFFECTS OF COMPLETE VERSUS INCOMPLETE MITRAL-VALVE REPAIR IN EXPERIMENTAL MITRAL REGURGITATION
Anesthetic and postoperative protocols for a canine model of reversible left ventricular volume overload.
可逆性左心室容量超负荷犬模型的麻醉和术后方案。
Left ventricular mechanics and myocyte function after correction of experimental chronic mitral regurgitation by combined mitral valve replacement and preservation of the native mitral valve apparatus.
通过联合二尖瓣置换术和保留原生二尖瓣装置纠正实验性慢性二尖瓣反流后的左心室力学和肌细胞功能。
  • DOI:
  • 发表时间:
    1992
  • 期刊:
  • 影响因子:
    37.8
  • 作者:
    Ishihara,K;Zile,MR;Kanazawa,S;Tsutsui,H;Urabe,Y;DeFreyte,G;Carabello,BA
  • 通讯作者:
    Carabello,BA
STRUCTURAL BASIS FOR CHANGES IN LEFT-VENTRICULAR FUNCTION AND GEOMETRY BECAUSE OF CHRONIC MITRAL REGURGITATION AND AFTER CORRECTION OF VOLUME OVERLOAD
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BLASE A CARABELLO其他文献

BLASE A CARABELLO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BLASE A CARABELLO', 18)}}的其他基金

UPGRADE OF ANGIOGRAPHIC FACILITY
血管造影设施升级
  • 批准号:
    3521123
  • 财政年份:
    1991
  • 资助金额:
    $ 17.05万
  • 项目类别:
CONTRACTILITY IN EXPERIMENTAL VOLUME OVERLOAD
实验体积过载中的收缩性
  • 批准号:
    3354270
  • 财政年份:
    1988
  • 资助金额:
    $ 17.05万
  • 项目类别:
BETA BLOCKADE IN MITRAL REGURGITATION
β 阻断治疗二尖瓣反流
  • 批准号:
    2218733
  • 财政年份:
    1988
  • 资助金额:
    $ 17.05万
  • 项目类别:
BETA BLOCKADE IN MITRAL REGURGITATION
β 阻断治疗二尖瓣反流
  • 批准号:
    2218731
  • 财政年份:
    1988
  • 资助金额:
    $ 17.05万
  • 项目类别:
CONTRACTILITY IN EXPERIMENTAL VOLUME OVERLOAD
实验体积过载中的收缩性
  • 批准号:
    3354266
  • 财政年份:
    1988
  • 资助金额:
    $ 17.05万
  • 项目类别:
CONTRACTILITY IN EXPERIMENTAL VOLUME OVERLOAD
实验体积过载中的收缩性
  • 批准号:
    3354268
  • 财政年份:
    1988
  • 资助金额:
    $ 17.05万
  • 项目类别:
CONTRACTILITY IN EXPERIMENTAL VOLUME OVERLOAD
实验体积过载中的收缩性
  • 批准号:
    3354271
  • 财政年份:
    1988
  • 资助金额:
    $ 17.05万
  • 项目类别:
BETA BLOCKADE IN MITRAL REGURGITATION
β 阻断治疗二尖瓣反流
  • 批准号:
    2218732
  • 财政年份:
    1988
  • 资助金额:
    $ 17.05万
  • 项目类别:
CONTRACTILITY IN EXPERIMENTAL VOLUME OVERLOAD
实验体积过载中的收缩性
  • 批准号:
    3354269
  • 财政年份:
    1988
  • 资助金额:
    $ 17.05万
  • 项目类别:
CORONARY BLOOD FLOW IN SUB CORONARY AORTIC STENOSIS
冠状动脉瓣下狭窄的冠状动脉血流
  • 批准号:
    3352302
  • 财政年份:
    1985
  • 资助金额:
    $ 17.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了